In 2018, Juge et al. first demonstrated that the MUC5B promoter variant significantly increases the risk of developing ILD in patients with rheumatoid arthritis (RA), particularly in those with a UIP pattern [7]. Here, MUC5B is linked to idiopathic pulmonary fibrosis.